Figure 6
Figure 6. Hematopoietic phenotype of Pparg−/− mice. (A) Representative example of genotyping by RT-PCR of Pparg fl/fl.Mx1-Cre or control Pparg fl/fl mice treated with poly(I:C) (625 mg intraperitoneally every 2 days for 8 days). (B) FLT3L-induced proliferation of cPparg−/− cells in the presence of rosiglitazone or GW9662 (n = 4; data expressed relative to DMSO in control LSK cells). (C) Frequency of LSK cells, long-term HSCs (LT-HSCs; LSKCD34−FLT3−), short-term HSCs (ST-HSCs; LSKCD34+FLT3−), and MPP cells (LSKCD34+FLT3+) in the BM of cPparg−/− or control Pparg fl/fl mice treated with poly(I:C) (n = 3). (E) Myeloid (Mac1+Gr1+), B (CD19+) and T (Thy1+) cell contribution of donor-derived PB cells 8-10 weeks after transplantation of 0.5 × 106 cPparg−/− or control Ppargfl/fl BM and competitor (CD45.1+ C57BL/6) BM cells into lethally irradiated CD45.1+CD45.2+ C57BL/6 mice (n = 9 for Ppargfl/fl; n = 12 for cPparg−/−).

Hematopoietic phenotype of Pparg−/− mice. (A) Representative example of genotyping by RT-PCR of Pparg fl/fl.Mx1-Cre or control Pparg fl/fl mice treated with poly(I:C) (625 mg intraperitoneally every 2 days for 8 days). (B) FLT3L-induced proliferation of cPparg−/− cells in the presence of rosiglitazone or GW9662 (n = 4; data expressed relative to DMSO in control LSK cells). (C) Frequency of LSK cells, long-term HSCs (LT-HSCs; LSKCD34−FLT3−), short-term HSCs (ST-HSCs; LSKCD34+FLT3−), and MPP cells (LSKCD34+FLT3+) in the BM of cPparg−/− or control Pparg fl/fl mice treated with poly(I:C) (n = 3). (E) Myeloid (Mac1+Gr1+), B (CD19+) and T (Thy1+) cell contribution of donor-derived PB cells 8-10 weeks after transplantation of 0.5 × 106cPparg−/− or control Ppargfl/fl BM and competitor (CD45.1+ C57BL/6) BM cells into lethally irradiated CD45.1+CD45.2+ C57BL/6 mice (n = 9 for Ppargfl/fl; n = 12 for cPparg−/−).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal